A new surveillance report from the European Centre for Disease Prevention and Control (ECDC) shows wide ranges of antibiotic consumption in Europe, with no significant trends in mean consumption observed.

The fourth annual report of the European Surveillance of Antimicrobial Consumption Network (ESAC-Net) is based on antimicrobial consumption data from the community and the hospital sector in European Union/European Economic Area (EU/EEA) countries for the years 2013 and 2014. It shows that population-weighted EU/EEA mean community consumption in 2014 was 21.9 defined daily doses (DDD) per 1,000 inhabitants per day—the same level as 2013—with the highest consumption in Greece (35.1 DDD per 1,000 inhabitants/day) and the lowest in the Netherlands (10.6 DDD per 1,000 inhabitants/day). The most commonly used subgroups of antibiotics were combinations of penicillins, including beta-lactamase inhibitors and penicillins with extended spectrum, followed by macrolides and tetracyclines.

An analysis of EU/EEA data from the previous 5 years did not reveal any significant trend in the mean overall consumption across Europe from 2010 through 2014, but two countries (Cyprus and Sweden) showed a significant decreasing trend in community antibiotic consumption, while a significant increasing trend was observed in the United Kingdom. Significant and divergent trends were observed for two quality indicators measuring consumption of beta-lactamase-sensitive penicillins and combinations of penicillins, including beta-lactamase inhibitors.

In the hospital sector, the population-weighted EU/EEA mean consumption was 2.0 DDD per 1,000 inhabitants/day, with no significant trends in the mean consumption apparent for the previous 5 years. Hospital consumption varied from 1.0 DDD per 1,000 inhabitants/day in the Netherlands to 2.6 DDD per 1,000 inhabitants/day in Finland. The most frequently used subgroups of antibiotics were penicillins, other beta-lactam antibiotics including cephalosporins, and quinolones. A significant increasing trend in the use of carbapenems and polymixins for serious infections was reported in several countries.
May 28 ECDC antimicrobial consumption report

#MicroGuide #StopSuperbugs #Antimicrobial #Antibiotic Resistance